OVERVIEW

An assessment of the magnitude of the clinical benefits of trastuzumab for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study.

TITLE OF PUBLICATION

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

AUTHORS

Untch, M., Gelber, R.D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B. and de Azambuja, E.

PUBLICATION REFERENCE

Annals of Oncology | Volume 19 | Issue 6 | Pages 1090-1096 | June 2008